mapatumumab
conatumumab
monoclonal
guselkumab
carlumab
lucatumumab
cibisatamab
-xizu-
sibrotuzumab
inotuzumab ozogamicin
-i-
oleclumab
polyantigenic
heterophile
patritumab
immunoantigen
antigenomic
drozitumab
multiantigenic
idiospecific
alacizumab
panitumumab
oportuzumab monatox
tabalumab
dalotuzumab
lenzilumab
polyclonal
siltuximab
perakizumab
ABO antibodies
robatumumab
pancytokeratin
-lim-
dorlixizumab
bispecific
nofetumomab
toralizumab
-a-
hyperimmunoglobulin
immunospecific
antisubstance
teplizumab
-toxa-
antihuman
pritumumab
immunoadsorbent
durvalumab
lexatumumab
agonistic monoclonal antibody
immunoglobulin G